What is AbbVie's expected EPS for Q2 2026?

Analysts expect AbbVie (ABBV) to report consensus EPS of approximately $3.65 for Q2 2026. Estimates range from $3.57 to $3.81.

What revenue do analysts expect for AbbVie in Q2 2026?

The consensus revenue forecast for AbbVie (ABBV) in Q2 2026 is approximately $16.8B. Forecasts range from $16.5B to $17B.

How many analysts cover AbbVie?

12 analysts contribute to the AbbVie (ABBV) Q2 2026 consensus estimate.

Has AbbVie beaten earnings estimates recently?

AbbVie beat analyst EPS estimates in 2 of the last 2 quarters. AbbVie beat revenue estimates in 2 of 2. In the most recent quarter (Q1 2026), AbbVie EPS beat by 2.2% and revenue beat by 1.9%.

When does AbbVie report Q2 2026 earnings?

AbbVie (ABBV) is expected to report Q2 2026 earnings on July 31, 2026 before market open.

ABBV Q2 2026 earnings estimate

Consensus EPS · Q2 2026

$3.65

Consensus revenue · Q2 2026

$16.8B

Analysts

Expected report

Jul 31, 2026

Before open

Upcoming earnings

Locks in 7 days 13 hours · BMO: Locks 8:00 PM ET previous day

Revenue$16.8B$16.5B – $17B

EPS$3.65$3.57 – $3.81

What to watch

Analyst ratings: Mixed

Make your prediction

Analyst consensus

Based on estimates from 12 analysts.

Metric	Low	Consensus	High
Revenue	$16.5B	$16.8B	$17B
EPS	$3.57	$3.65	$3.81
EBITDA	$5.7B	$5.7B	$5.8B
EBIT	$3.3B	$3.3B	$3.3B
Net income	$6.3B	$6.4B	$6.7B

Revenue$16.8B
EPS$3.65
EBITDA$5.7B
EBIT$3.3B
Net income$6.4B

Historical beat/miss

Actual reported results vs. analyst consensus at the time. Positive = beat, negative = miss.

Period	Rev. actual	Rev. est.	Rev. surprise	EPS actual	EPS est.	EPS surprise
Q1 2026	$15B	$14.7B	+1.9%	$2.65	$2.59	+2.2%
Q4 2025	$16.6B	$16.4B	+1.3%	$2.71	$2.65	+2.2%

Q1 2026+1.9%+2.2%
Q4 2025+1.3%+2.2%

Estimate revisions

How analyst consensus estimates have changed over the past 90 days.

Collecting data

Revision trends appear once we have collected at least two daily snapshots for this period.

Community vs analysts

See how the TickerLeague crowd's forecast stacks up against Wall Street.

Be the first to predict

No community consensus for AbbVie (ABBV) Q2 2026 yet. Make a prediction to start the crowd forecast.

Make your prediction

Analyst price target

Based on price targets from 9 analysts.

Low: $223.00
Consensus: $273.23
Median: $278.00
High: $300.00
Current: $253.30
Upside: +7.9%

Upside calculated vs most recent trading price of $253.30.

Analyst ratings

Consensus: Buy — based on 41 analyst ratings.

Buy 29Hold 11Sell 1

24-month trend

Recent analyst actions

Date	Firm	Action	From	To
Jul 15, 2026	Citigroup	maintain	Neutral	Neutral
Jul 13, 2026	UBS	maintain	Neutral	Neutral
Jul 13, 2026	BMO Capital	maintain	Outperform	Outperform
Jul 10, 2026	Wells Fargo	maintain	Overweight	Overweight
Jul 10, 2026	RBC Capital	maintain	Outperform	Outperform
Jul 10, 2026	B of A Securities	maintain	Buy	Buy
Jul 9, 2026	JP Morgan	maintain	Overweight	Overweight
Jul 9, 2026	Guggenheim	maintain	Buy	Buy
Jul 6, 2026	Cantor Fitzgerald	maintain	Overweight	Overweight
Jun 23, 2026	Piper Sandler	maintain	Overweight	Overweight

Jul 15, 2026CitigroupNeutral
Jul 13, 2026UBSNeutral
Jul 13, 2026BMO CapitalOutperform
Jul 10, 2026Wells FargoOverweight
Jul 10, 2026RBC CapitalOutperform
Jul 10, 2026B of A SecuritiesBuy
Jul 9, 2026JP MorganOverweight
Jul 9, 2026GuggenheimBuy
Jul 6, 2026Cantor FitzgeraldOverweight
Jun 23, 2026Piper SandlerOverweight

Frequently asked questions

AbbVie (ABBV) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

ABBV Overview

Counters

Income Statement

Cash Flow

Capital Return

How this company returns cash to shareholders — buybacks, dividends, and stock splits.

Forecast & Valuation